Using FreeStyle Libre for lifestyle changes in type 2 diabetes patients
Official title: Patient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes Patients
Run by Seoul National University Hospital · NCT04932928 · Data updated 2026-11-12
This study is testing if using the FreeStyle Libre continuous glucose monitor helps people with type 2 diabetes make better lifestyle changes compared to traditional blood sugar checks.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years to 80 Years |
| Sex | All |
| Enrollment | 126 (estimated) |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | March 23, 2021 |
| Main results expected | September 23, 2022 |
| Study ends | March 23, 2023 |
| Registry record updated | June 21, 2021 |
| Trial ID | NCT04932928 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 19-80 diagnosed with uncontrolled type 2 diabetes mellitus and an HbA1c level between 7.0 - 10.0%.
✕Probably not a fit
Patients with other types of diabetes, those using prandial insulin, or individuals with severe skin conditions that prevent the use of CGM devices may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of Continuous Glucose Monitoring (CGM) using the FreeStyle Libre device compared to Self-Monitoring of Blood Glucose (SMBG) in patients with type 2 diabetes. The study will involve 126 participants who have an elevated HbA1c between 7.0 - 10.0% and are not using prandial insulin. Participants will receive personalized education on lifestyle modifications and will be monitored over a 12-week period to assess changes in their glycemic control. The study is randomized and open-label, with participants assigned to either the CGM or SMBG group.
Why it matters
Potential benefit: If successful, this approach could significantly improve glycemic control and lifestyle management for patients with type 2 diabetes.
How similar studies have gone: Other studies have shown promising results using CGM for diabetes management, indicating that this approach has potential based on previous findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 19-80 * Diagnosed with type 2 diabetes mellitus (DM) * Uncontrolled type 2 DM: HbA1c 7.0-10.0% * Signed informed consent Exclusion Criteria: * Diagnosed with other types of diabetes mellitus (i.e. Type 1 DM) * Use of prandial insulin * Change in diabetes medication in the preceding 3 months * Pregnant/lactating women * Addiction to drugs and alcohol * Use of medications that result in drug-induced hyperglycemia (i.e. steroid) * Severe liver disease * End-stage renal disease (i.e. on dialysis) * Unable to wear CGM devices due to dermatologic side effects (i.e. severe burn, inflammation, active skin infection, severe skin reactions, hypertrichosis, etc.) * Conditions that impact the stability of HbA1c measurement
Where it's running
-
Seoul National University Hospital
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Young Min Cho, MD, PhD — Seoul National University Hospital
- Study coordinator: Hun Jee Choe, MD
- Email: hunjeechoe@snu.ac.kr
- Phone: 82-2-2072-1965
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin
This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.